Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104286 | 0.84 | SLC1A3 (0.33) | SLC1A3SLC1A2SLC1A1USP2TSHR | |
| SCHEMBL428738 | 0.76 | — | — | |
| SCHEMBL10888440 | 0.76 | — | — | |
| SCHEMBL6364746 | 0.71 | CA2 (0.39) | SLC1A3SLC1A2SLC1A1USP2TSHR | |
| SCHEMBL5101517 | 0.71 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1USP2TSHR | |
| SCHEMBL13788562 | 0.70 | USP2 (0.34) | SLC1A3SLC1A2SLC1A1USP2TSHR | |
| SCHEMBL9463468 | 0.70 | CA1 (0.41) | TSHRCA2CA1MAPK1 | |
| SCHEMBL8108998 | 0.69 | MAPT (0.43) | TSHRCA2CA1MAPK1 | |
| SCHEMBL11293240 | 0.69 | TDP1 (0.45) | — | |
| SCHEMBL10767618 | 0.68 | USP2 (0.33) | SLC1A3SLC1A2SLC1A1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-7112692-B2 | β-ketophosphonates | RHODIA CONSUMER SPECIALTIES, LIMITED (GB) | 2006-09-26 | — | — | US | disclosed |
| EP-1430065-B1 | BETA-KETOPHOSPHONATES | RHODIA CONS SPEC LTD (GB) | 2005-02-02 | — | — | EP | disclosed |
| US-20040267040-A1 | Beta-ketophosphonates | RHODIA CONSUMER SPECIALITIES LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
| EP-1430065-A1 | BETA-KETOPHOSPHONATES | RHODIA CONSUMER SPECIALTIES LIMITED (GB) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027129-A1 | BETA-KETOPHOSPHONATES | RHODIA CONSUMER SPECIALTIES LIMITED (GB) | 2003-04-03 | — | — | WO | disclosed |
| US-6528656-B1 | Does not disrupt medium on which in vivo measurement is taken | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2003-03-04 | — | — | US | disclosed |
| EP-1064287-A1 | USE OF AMINOPHOSPHONATES AS 31 P-NMR PH INDICATORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047527-A1 | USE OF AMINOPHOSPHONATES AS31P NMR pH INDICATORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CN RS) (FR) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | SLC1A3 335/4885SLC1A2 751/4885SLC1A1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.